Revenue Summary of Arch Biopartners Inc.

Arch Biopartners Inc.'s latest annual revenue in 2023 was 1.98 Million CAD , up 105.63% from previous year.
Arch Biopartners Inc.'s latest quarterly revenue in 2024 Q3 was - CAD , down -100.0% from previous quarter.
Arch Biopartners Inc. reported a annual revenue of 964.68 Thousand CAD in annual revenue 2022, down -75.18% from previous year.
Arch Biopartners Inc. reported a annual revenue of 3.88 Million CAD in annual revenue 2021, up 5625.22% from previous year.
Arch Biopartners Inc. reported a quarterly revenue of 2.18 Million CAD for 2024 Q2, up 632.65% from previous quarter.
Arch Biopartners Inc. reported a quarterly revenue of - CAD for 2024 Q3, down -100.0% from previous quarter.

Annual Revenue Chart of Arch Biopartners Inc. (2023 - 1997)

Historical Annual Revenue of Arch Biopartners Inc. (2023 - 1997)

Year	Revenue	Revenue Growth
2023	1.98 Million CAD	105.63%
2022	964.68 Thousand CAD	-75.18%
2021	3.88 Million CAD	5625.22%
2020	67.88 Thousand CAD	-27.69%
2019	93.87 Thousand CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	0.0%
2016	- CAD	-100.0%
2015	37.64 Thousand CAD	-26.37%
2014	51.12 Thousand CAD	35.65%
2013	37.68 Thousand CAD	0.0%
2012	- CAD	0.0%
2011	- CAD	0.0%
2010	- CAD	0.0%
2009	- CAD	-100.0%
2008	3.65 Million CAD	122.63%
2007	1.64 Million CAD	3.01%
2006	1.59 Million CAD	-16.41%
2005	1.9 Million CAD	-28.77%
2004	2.67 Million CAD	-6.38%
2003	2.85 Million CAD	188281.62%
2002	1518.00 CAD	-10.97%
2001	1705.00 CAD	-99.51%
2000	349.44 Thousand CAD	601.82%
1999	49.79 Thousand CAD	-50.21%
1998	100 Thousand CAD	996.85%
1997	9117.00 CAD	0.0%

Year	Revenue	Revenue Growth
2024 Q1	298.14 Thousand CAD	127.13%
2024 Q2	2.18 Million CAD	632.65%
2024 Q3	- CAD	-100.0%
2023 Q2	2.53 Million CAD	482.31%
2023 Q3	116.37 Thousand CAD	-95.4%
2023 Q4	-1.09 Million CAD	-1044.28%
2023 FY	1.98 Million CAD	105.63%
2023 Q1	434.71 Thousand CAD	173.22%
2022 Q4	-593.7 Thousand CAD	0.0%
2022 Q3	- CAD	-100.0%
2022 Q2	1.12 Million CAD	158.33%
2022 Q1	434.9 Thousand CAD	-76.72%
2022 FY	964.68 Thousand CAD	-75.18%
2021 Q1	- CAD	100.0%
2021 Q4	1.86 Million CAD	-6.44%
2021 FY	3.88 Million CAD	5625.22%
2021 Q3	1.99 Million CAD	9371.56%
2021 Q2	21.08 Thousand CAD	0.0%
2020 Q1	26.08 Thousand CAD	-59.47%
2020 Q2	29.57 Thousand CAD	13.38%
2020 Q3	29.57 Thousand CAD	0.0%
2020 Q4	-17.33 Thousand CAD	-158.63%
2020 FY	67.88 Thousand CAD	-27.69%
2019 Q1	- CAD	0.0%
2019 FY	93.87 Thousand CAD	0.0%
2019 Q4	64.34 Thousand CAD	117.92%
2019 Q2	- CAD	0.0%
2019 Q3	29.52 Thousand CAD	0.0%
2018 Q2	- CAD	0.0%
2018 Q3	- CAD	0.0%
2018 Q1	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q4	- CAD	0.0%
2017 Q1	- CAD	0.0%
2017 Q2	- CAD	0.0%
2017 Q4	- CAD	0.0%
2017 FY	- CAD	0.0%
2017 Q3	- CAD	0.0%
2016 FY	- CAD	-100.0%
2016 Q2	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 Q4	- CAD	0.0%
2016 Q1	- CAD	-100.0%
2015 FY	37.64 Thousand CAD	-26.37%
2015 Q1	37.59 Thousand CAD	-26.46%
2015 Q4	43.00 CAD	0.0%
2015 Q3	- CAD	0.0%
2015 Q2	- CAD	-100.0%
2014 Q1	- CAD	-100.0%
2014 FY	51.12 Thousand CAD	35.65%
2014 Q2	12 Thousand CAD	0.0%
2014 Q4	51.12 Thousand CAD	411.25%
2014 Q3	10 Thousand CAD	-16.67%
2013 Q1	- CAD	0.0%
2013 FY	37.68 Thousand CAD	0.0%
2013 Q4	37.68 Thousand CAD	0.0%
2013 Q2	- CAD	0.0%
2013 Q3	- CAD	0.0%
2012 Q4	- CAD	0.0%
2012 Q3	- CAD	0.0%
2012 FY	- CAD	0.0%
2012 Q1	- CAD	0.0%
2012 Q2	- CAD	0.0%
2011 Q1	- CAD	0.0%
2011 Q3	- CAD	0.0%
2011 FY	- CAD	0.0%
2011 Q4	- CAD	0.0%
2011 Q2	- CAD	0.0%
2010 Q4	- CAD	0.0%
2010 Q1	- CAD	0.0%
2010 Q3	- CAD	0.0%
2010 FY	- CAD	0.0%
2010 Q2	- CAD	0.0%
2009 Q1	525.82 Thousand CAD	-73.77%
2009 Q2	430.78 Thousand CAD	-18.07%
2009 Q3	- CAD	-100.0%
2009 FY	- CAD	-100.0%
2009 Q4	- CAD	0.0%
2008 Q3	824.02 Thousand CAD	173.23%
2008 Q1	808.85 Thousand CAD	135.39%
2008 FY	3.65 Million CAD	122.63%
2008 Q4	2 Million CAD	143.26%
2008 Q2	301.58 Thousand CAD	-62.71%
2007 FY	1.64 Million CAD	3.01%
2007 Q3	263.18 Thousand CAD	16.19%
2007 Q4	343.62 Thousand CAD	30.56%
2007 Q2	226.51 Thousand CAD	-73.4%
2007 Q1	851.59 Thousand CAD	279.43%
2006 Q1	252.54 Thousand CAD	-75.48%
2006 Q2	110.2 Thousand CAD	-56.36%
2006 Q3	407.89 Thousand CAD	270.11%
2006 Q4	224.43 Thousand CAD	-44.98%
2006 FY	1.59 Million CAD	-16.41%
2005 FY	1.9 Million CAD	-28.77%
2005 Q4	1.03 Million CAD	318.15%
2005 Q3	246.33 Thousand CAD	-34.84%
2005 Q2	378.07 Thousand CAD	-69.86%
2005 Q1	1.25 Million CAD	259.14%
2004 Q1	- CAD	0.0%
2004 Q4	349.23 Thousand CAD	-51.82%
2004 Q3	724.78 Thousand CAD	107.64%
2004 FY	2.67 Million CAD	-6.38%
2004 Q2	349.05 Thousand CAD	0.0%
2003 Q1	-5609.00 CAD	0.0%
2003 FY	2.85 Million CAD	188281.62%
2003 Q3	- CAD	0.0%
2003 Q2	- CAD	100.0%
2003 Q4	- CAD	0.0%
2002 Q1	199.00 CAD	87.74%
2002 FY	1518.00 CAD	-10.97%
2002 Q3	10.78 Thousand CAD	0.0%
2002 Q4	- CAD	-100.0%
2002 Q2	- CAD	-100.0%
2001 FY	1705.00 CAD	-99.51%
2001 Q3	800.00 CAD	33.33%
2001 Q2	600.00 CAD	-96.36%
2001 Q1	16.46 Thousand CAD	-71.98%
2001 Q4	106.00 CAD	-86.75%
2000 FY	349.44 Thousand CAD	601.82%
2000 Q3	78.18 Thousand CAD	-60.12%
2000 Q4	58.75 Thousand CAD	-24.85%
2000 Q2	196.04 Thousand CAD	293.73%
2000 Q1	49.79 Thousand CAD	4979000.0%
1999 Q2	1.00 CAD	-100.0%
1999 Q1	99.99 Thousand CAD	9999800.0%
1999 FY	49.79 Thousand CAD	-50.21%
1999 Q3	1.00 CAD	0.0%
1999 Q4	1.00 CAD	0.0%
1998 Q2	1.00 CAD	0.0%
1998 Q4	1.00 CAD	0.0%
1998 FY	100 Thousand CAD	996.85%
1998 Q3	1.00 CAD	0.0%
1997 FY	9117.00 CAD	0.0%

Peer Revenue Comparison of Arch Biopartners Inc.

Name	Revenue	Revenue Difference
Evofem Biosciences, Inc.	18.21 Million USD	89.112%
Arch Therapeutics, Inc.	75.72 Thousand USD	-2519.57%
CSL Limited	14.69 Billion USD	99.986%
Santhera Pharmaceuticals Holding AG	122.95 Million USD	98.387%
Regen BioPharma, Inc.	236.56 Thousand USD	-738.537%
BioStem Technologies, Inc.	16.68 Million USD	88.112%
Capstone Therapeutics Corp.	48.35 Million USD	95.898%
Qrons Inc.	- USD	-Infinity%
Nascent Biotech, Inc.	- USD	-Infinity%
Northwest Biotherapeutics, Inc.	1.93 Million USD	-2.673%
Oncotelic Therapeutics, Inc.	70 Thousand USD	-2733.776%
Skye Bioscience, Inc.	- USD	-Infinity%
ProtoKinetix, Incorporated	- USD	-Infinity%
Rebus Holdings, Inc.	- USD	-Infinity%
Acro Biomedical Co., Ltd.	658.5 Thousand USD	-201.237%
Burzynski Research Institute, Inc.	- USD	-Infinity%
Genscript Biotech Corporation	839.52 Million USD	99.764%
Neon Bloom, Inc.	- USD	-Infinity%
Adynxx, Inc.	- USD	-Infinity%
Eiger BioPharmaceuticals, Inc.	15.77 Million USD	87.424%
Nanobac Pharmaceuticals, Incorporated	17.62 Thousand USD	-11157.267%
Institute of Biomedical Research Corp.	- USD	-Infinity%
SQZ Biotechnologies Company	21.47 Million USD	90.764%
Intellipharmaceutics International Inc.	65.72 Thousand USD	-2917.957%
Propanc Biopharma, Inc.	- USD	-Infinity%
Mesoblast Limited	5.9 Million USD	66.39%
Marizyme, Inc.	645.81 Thousand USD	-207.156%
Genus plc	668.8 Million USD	99.703%
VioQuest Pharmaceuticals, Inc.	- USD	-Infinity%
Pharming Group N.V.	245.31 Million USD	99.191%
Therapeutic Solutions International, Inc.	98.99 Thousand USD	-1903.801%
CNBX Pharmaceuticals Inc.	410.16 Thousand USD	-383.621%
Nymox Pharmaceutical Corporation	- USD	-Infinity%
ContraFect Corporation	- USD	-Infinity%
PsyBio Therapeutics Corp.	- USD	-Infinity%
Sienna Biopharmaceuticals, Inc.	- USD	-Infinity%
RegeneRx Biopharmaceuticals, Inc.	76.76 Thousand USD	-2484.181%
IMV Inc.	- USD	-Infinity%
AXIM Biotechnologies, Inc.	39.51 Thousand USD	-4919.594%
MultiCell Technologies, Inc.	49.32 USD	-4021884.996%
ONE Bio Corp.	52.29 Million USD	96.207%
Accustem Sciences Inc.	- USD	-Infinity%
RVL Pharmaceuticals plc	49.72 Million USD	96.01%
Arno Therapeutics, Inc.	- USD	-Infinity%
EV Biologics, Inc.	48.9 Thousand USD	-3956.53%
Q BioMed Inc.	284.35 Thousand USD	-597.601%
Emmaus Life Sciences, Inc.	29.59 Million USD	93.298%
Mosaic ImmunoEngineering Inc.	- USD	-Infinity%
Biomind Labs Inc.	- USD	-Infinity%
American Oriental Bioengineering, Inc.	145.09 Million USD	98.633%
Provectus Biopharmaceuticals, Inc.	557.71 Thousand USD	-255.676%
TetraLogic Pharmaceuticals Corporation	- USD	-Infinity%
GlobeStar Therapeutics Corporation	- USD	-Infinity%
THC Farmaceuticals, Inc.	- USD	-Infinity%
Curative Biotechnology, Inc.	- USD	-Infinity%
GB Sciences, Inc.	- USD	-Infinity%
Alpha Cognition Inc.	- USD	-Infinity%
HST Global, Inc.	- USD	-Infinity%
Wesana Health Holdings Inc.	- USD	-Infinity%
Halberd Corporation	999.00 USD	-198462.863%
Enzolytics Inc.	52.79 Thousand USD	-3657.184%
Agentix Corp.	- USD	-Infinity%
Resverlogix Corp.	- USD	-Infinity%
Nuo Therapeutics, Inc.	608.52 Thousand USD	-225.976%
MetaStat, Inc.	- USD	-Infinity%
argenx SE	1.22 Billion USD	99.838%
Enzon Pharmaceuticals, Inc.	- USD	-Infinity%
Endonovo Therapeutics, Inc.	140.24 Thousand USD	-1314.443%
RespireRx Pharmaceuticals Inc.	- USD	-Infinity%
GeneThera, Inc.	- USD	-Infinity%
Inhibitor Therapeutics, Inc.	- USD	-Infinity%
AVAX Technologies, Inc.	617.38 Thousand USD	-221.298%
Zenith Capital Corp.	- USD	-Infinity%
Ember Therapeutics, Inc.	- USD	-Infinity%
Anthera Pharmaceuticals, Inc.	- USD	-Infinity%
Sigyn Therapeutics, Inc.	- USD	-Infinity%
WPD Pharmaceuticals Inc.	- USD	-Infinity%
Cotinga Pharmaceuticals Inc.	- USD	-Infinity%
Kadimastem Ltd	- USD	-Infinity%
Helix BioMedix, Inc.	997.72 Thousand USD	-98.816%
VitaSpring Biomedical Co. Ltd.	- USD	-Infinity%
Oncology Pharma Inc.	- USD	-Infinity%
Reve Technologies, Inc.	- USD	-Infinity%
LadRx Corporation	- USD	-Infinity%
Cell Source, Inc.	- USD	-Infinity%
Regen BioPharma, Inc.	236.56 Thousand USD	-738.537%
NovAccess Global Inc.	- USD	-Infinity%
Affymax, Inc.	1.36 Million USD	-44.897%
Itoco Inc.	- USD	-Infinity%
Rasna Therapeutics, Inc.	- USD	-Infinity%
Pathfinder Cell Therapy, Inc.	- USD	-Infinity%
Mobile Lads Corp.	- USD	-Infinity%
CytoDyn Inc.	- USD	-Infinity%
Claritas Pharmaceuticals, Inc.	- USD	-Infinity%
NDT Pharmaceuticals Inc.	- USD	-Infinity%
NanoSphere Health Sciences Inc.	- USD	-Infinity%
Alseres Pharmaceuticals, Inc.	473.73 Thousand USD	-318.729%
SYBLEU INC	11.69 Thousand USD	-16860.012%
Advanced Proteome Therapeutics Corporation	- USD	-Infinity%
ImmunoCellular Therapeutics, Ltd.	- USD	-Infinity%
International Stem Cell Corporation	7.78 Million USD	74.533%
Bioxytran, Inc.	- USD	-Infinity%
GlobeImmune, Inc.	- USD	-Infinity%
Predictive Technology Group, Inc.	- USD	-Infinity%
ProText Mobility, Inc.	- USD	-Infinity%
Cardax, Inc.	- USD	-Infinity%
VG Life Sciences Inc.	- USD	-Infinity%
Kaleido Biosciences, Inc.	- USD	-Infinity%
Advaxis, Inc.	13 Thousand USD	-15158.792%
Adhera Therapeutics, Inc.	- USD	-Infinity%
RenovaCare, Inc.	- USD	-Infinity%
Regnum Corp.	- USD	-Infinity%
Innovation Pharmaceuticals Inc.	- USD	-Infinity%
Neutra Corp.	39.53 Thousand USD	-4917.562%
Windtree Therapeutics, Inc.	- USD	-Infinity%
PureTech Health plc	3.33 Million USD	40.431%
Coeptis Therapeutics, Inc.	- USD	-Infinity%
IXICO plc	6.66 Million USD	70.238%
IntelGenx Technologies Corp.	1.03 Million USD	-90.918%
Gelesis Holdings, Inc.	25.76 Million USD	92.302%
CSL Limited	14.8 Billion USD	99.987%
Cellectis S.A.	755 Thousand USD	-162.734%

Global Stocks Search

Arch Biopartners Inc. (ACHFF)

Revenue Summary of Arch Biopartners Inc.

Annual Revenue Chart of Arch Biopartners Inc. (2023 - 1997)

Historical Annual Revenue of Arch Biopartners Inc. (2023 - 1997)

Peer Revenue Comparison of Arch Biopartners Inc.